Alaunos Therapeutics, Inc.
TCRTAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | downgrade | Buy →Neutral | Aug 15, 2023 |
| Laidlaw & Co. | downgrade | Buy →Hold | Aug 14, 2023 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | May 14, 2023 |
| Wells Fargo | upgrade | Equal Weight →Overweight | May 3, 2022 |
| Raymond James | maintain | Market Perform | Nov 8, 2021 |
| Raymond James | downgrade | Outperform →Market Perform | Aug 9, 2021 |
| Raymond James | maintain | Outperform | May 6, 2021 |
| Jefferies | downgrade | Buy →Hold | Mar 11, 2021 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Feb 28, 2021 |
| Raymond James | maintain | Outperform | Mar 2, 2020 |
| Raymond James | upgrade | Market Perform →Outperform | Nov 14, 2018 |
| JP Morgan | downgrade | Neutral →Underweight | Jun 17, 2018 |
| Wells Fargo | upgrade | Underperform →Market Perform | Aug 9, 2016 |
| BMO Capital | downgrade | Outperform →Market Perform | Jun 21, 2015 |
| Mizuho | downgrade | Buy →Neutral | Mar 9, 2015 |
| BMO Capital | upgrade | Underperform →Outperform | Jan 13, 2015 |
| Piper Sandler | upgrade | Underweight →Neutral | Mar 3, 2014 |
| Brinson Patrick | downgrade | Outperform →Market Perform | Mar 26, 2013 |
| Jefferies | maintain | Hold | Mar 25, 2013 |
| BMO Capital | downgrade | Market Perform →Underperform | Mar 25, 2013 |
| JP Morgan | downgrade | Overweight →Neutral | Mar 25, 2013 |
| Piper Sandler | downgrade | Neutral →Underweight | Mar 25, 2013 |
| Jefferies | downgrade | Buy →Hold | Dec 11, 2012 |
| Jefferies | maintain | Buy | Mar 1, 2012 |
Earnings History
Next report: Nov 17, 2026 · EPS est. $-15.75| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.41 | — | — | — |
| May 15, 2026 | $-0.59 | — | — | — |
| Mar 31, 2026 | $-0.40 | $-3.69 | $3.0K | $3.0K |
| Nov 14, 2025 | $-0.55 | $-4.90 | — | — |
| Aug 14, 2025 | $-0.63 | $-5.33 | — | — |
| May 15, 2025 | $-0.67 | $-6.44 | $2.0K | — |
| Mar 31, 2025 | $-0.46 | $-4.50 | $4.0K | — |
| Nov 14, 2024 | $-0.70 | $-4.50 | — | — |
News
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock is surging on Tuesday with a massive session volume of 191.48 million compared to the average volume of 826.167 thousand, according to Benzinga Pro data.
Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team BOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs (together with related entities, "Paragon"), a biotechnology company focused on the discovery and development of differentiated biologics, today announced that members of…
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Securities and Exchange Commission filing that showed the company approved and adopted its Second Amended and Restated By-Laws, effective immediately.